Cargando…
Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes
Teduglutide, a GLP-2 analogue, has been available in France since 2015 to treat short-bowel-syndrome (SBS)-associated chronic intestinal failure (CIF) but it remains very expensive. No real-life data on the number of potential candidates are available. The aim of this real-life study was to assess t...
Autores principales: | de Dreuille, Brune, Nuzzo, Alexandre, Bataille, Julie, Mailhat, Charlotte, Billiauws, Lore, Le Gall, Maude, Joly, Francisca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255523/ https://www.ncbi.nlm.nih.gov/pubmed/37299413 http://dx.doi.org/10.3390/nu15112448 |
Ejemplares similares
-
Malnutrition with Low Muscle Mass Is Common after Weaning off Home Parenteral Nutrition for Chronic Intestinal Failure
por: Wauters, Lucas, et al.
Publicado: (2023) -
Teduglutide for short bowel syndrome
Publicado: (2020) -
Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome
por: Schwartz, Lauren K, et al.
Publicado: (2016) -
Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure
por: Chen, Kristina, et al.
Publicado: (2019) -
Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure
por: Fifi, Amanda, et al.
Publicado: (2023)